FarmaKology-Incyte Partners with Qiagen to Create Diagnostic for Rare Blood Cancers

Would you like to submit an article, some interesting news, or get your startup featured? Send whatever you have to "abdul@farmakology.com", and happy to have you featured on our newsletter+21K Subs.

Jun 18, 2025

Today's Company

Nuravax

Nuravax is spearheading the use of immunotherapies in neurodegenerative disorders. We fully recognize the widespread impact of Alzheimer’s disease and other neurodegenerative conditions on millions of patients, caregivers, and families worldwide.Our revolutionary MultiTEP vaccine platform, built on over two decades of extensive research, was developed in collaboration with the Institute for Molecular Medicine, various universities, and the NIH.

News

AI start-up SandboxAQ creates new data to speed up drug discovery

SandboxAQ today announced the launch of SAIR (Structurally Augmented IC50 Repository), the largest-ever detailed dataset of protein-ligand pairs with annotated experimental potency data. Marking a major milestone in computational drug discovery, SAIR provides an unprecedented resource for researchers to advance AI models in drug discovery, significantly enhancing the speed and accuracy of binding affinity predictions.

MAIA Biotechnology Announces Master Clinical Supply Agreement with Roche for Hard-to-Treat Cancer Therapies

MAIA Biotechnology, Inc., a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced its entry into a clinical master supply agreement with Roche for future studies investigating the combination of MAIA’s telomere-targeting agent ateganosine (THIO), sequenced with Roche’s checkpoint inhibitor (CPI), atezolizumab (Tecentriq®), for the treatment of multiple hard-to-treat cancers.

AbbVie’s Qulipta Demonstrates Superiority in Migraine Prevention

AbbVie today announced positive topline results from its Phase 3 TEMPLE multicenter, randomized, double-blind, head-to-head study evaluating the tolerability, safety and efficacy of atogepant (QULIPTA^®/ AQUIPTA^®, 60 mg once daily) compared to the highest tolerated dose of topiramate (50, 75 or 100 mg/day) in adult patients with a history of four or more migraine days per month.

Incyte Partners with Qiagen to Create Diagnostic for Rare Blood Cancers

Incyte today announced that the U.S. Food and Drug Administration (FDA) has approved Monjuvi® (tafasitamab-cxix), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, in combination with rituximab and lenalidomide for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL).